

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Grand Pharmaceutical and Healthcare Holdings Limited

遠大醫藥健康控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

ENTERED INTO COOPERATIVE FRAMEWORK AGREEMENT ON RADIATION SAFETY AND ENVIRONMENTAL PROTECTION WITH NUCLEAR AND RADIATION SAFETY CENTER OF THE MINISTRY OF ECOLOGY AND ENVIRONMENT OF THE PRC

This announcement is made by the board of directors (the “**Board**”) of China Grand Pharmaceutical and Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Board is pleased to announce that the Group and Nuclear and Radiation Safety Center of the Ministry of Ecology and Environment of the PRC (“**Nuclear and Radiation Safety Center**”) have entered into a cooperative framework agreement (“**Cooperative Framework Agreement**”). The two parties share a common development strategy in radiation safety and environmental protection in use of nuclear technology, and will actively cooperate to build a strong partnership and achieve resource optimization by leveraging respective advantages.

Pursuant to the Cooperative Framework Agreement, both parties will carry out technological cooperation in nuclear and radiation safety and related fields, including research of key technology in use of nuclear and radiation safety, safety management and application of radioactive source, transportation of radioactive materials, professional training, technical consultation and information services, education on use of nuclear technology and radiation safety and so forth.

The Nuclear and Radiation Safety Center is the only public welfare institution in China that specializes in nuclear safety and technical support for radiation environment supervision and management. Its major responsibility is to provide a full scope of technical support for China's civil nuclear facilities and radiation environment supervision, including: technical support for nuclear safety and radiation environment supervision, studies in nuclear safety supervision policies and regulations for civil nuclear facilities, technical support for safety evaluation and supervision for civil nuclear facilities, technical support for safety evaluation and supervision for radiation environment, emergency response and evaluation of nuclear and radiation accidents, scientific research in nuclear safety and radiation protection, related technical consultation and information services, etc.

Under the stringent regulations in the field of radiopharmaceuticals, the Cooperative Framework Agreement entered into between the Group and the Nuclear and Radiation Safety Center will help the Group to deepen its understanding of regulatory requirements. It also demonstrates that China's national supervision authorities have faith in the Group's capability in use of nuclear technology and management competency. The Group will take this

opportunity to continuously enhance communication with national authorities and strictly abide by relevant laws and regulations, so as to cultivate more professionals in nuclear and radiation safety and environmental protection. This will lay a solid foundation for the in-depth expansion in research of radiopharmaceuticals in the future, and further contribute to promoting the development of China's radiopharmaceutical industry.

The Group is insightful and far-sighted in realizing the huge market potential of radiopharmaceuticals in anti-tumor field. It is one of the Group's focus areas in future strategic planning and has achieved fruitful results. The new drug application for the Group's anti-tumor product SIR-Spheres® Y-90 resin microspheres has been formally accepted by the National Medical Products Administration of the PRC this week. Furthermore, the Group owns six innovative first-in-class radionuclide-drug conjugates (RDC) for diagnostics and treatment of prostate cancer, clear cell renal cell carcinoma and glioblastoma. The variety and quantity of the Group's product pipeline in the field of anti-tumor radioactive pharmaceuticals are at the leading level in this industry.

Sticking to patients-centered and innovation-driven, the Group will continue to increase its investment in the field of anti-tumor radiopharmaceuticals. Through cooperating with the advanced pharmaceutical companies like Australia based Sirtex Medical Pty Ltd and Telix Pharmaceuticals Limited (ASX: TLX), the Group will continue to develop world-class innovative products for different cancer indications in response to unmet clinical needs and enrich product pipeline and improve supply chain, dedicating itself into building a world-leading radiopharmaceuticals platform integrating diagnostics and treatment. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its domestic industrial advantages and research and development capabilities, to accelerate commercialization process for innovative products and provide Chinese cancer patients with more advanced and diverse treatment options.

By order of the Board
**China Grand Pharmaceutical and
Healthcare Holdings Limited**
Liu Chengwei
Chairman

Hong Kong, 26 November 2020

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Liu Chengwei, Mr. Hu Bo, Dr. Shao Yan and Dr. Niu Zhanqi and three independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*